Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Tempest Therapeutics

Clinical trials sponsored by Tempest Therapeutics, explained in plain language.

Tempest Therapeutics TPST NASDAQ

A clinical-stage oncology company developing small molecule and immuno-oncology therapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet recruiting 1 Completed 1

New pill plus immunotherapy shows promise for liver cancer

Disease control Not yet recruiting

This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned t…

Phase: PHASE3 • Sponsor: Tempest Therapeutics • Aim: Disease control

Last updated Jun 26, 2026 13:20 UTC